Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

We recommend the following alternatives

W IP   IF     H
REACTIVITY SENSITIVITY MW (kDa) SOURCE
170-220 Rabbit

Product Usage Information

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Specificity / Sensitivity

MRP1/ABCC Antibody recognizes endogenous levels of total MRP1 protein. This antibody does not cross-react with other MRP proteins.


Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gln271 of human MRP1 protein. Antibodies are purified by protein A and peptide affinity chromatography.

Multidrug resistance-associated protein 1 (MRP1/ABCC1) is a member of the MRP subfamily of ATP-binding cassette (ABC) transporters (1). MRP1/ABCC1 protein functions as an organic anion transporter. It has a broad range of substrates, including antineoplastic or therapeutic agents and the glutathione (GSH) conjugates of these compounds. MRP1/ABCC1 also transports physiological substrates such as folates, GSH and GSH disulfide (GSSG) conjugates of steroids, leukotrienes, and prostaglandins (2,3).

Although MRP1/ABCC1 is generally expressed in normal tissue, upregulation of MRP1/ABCC1 has been found in a variety of solid tumors, including small cell lung cancer, breast cancer, and prostate cancer (1,4,5). Research studies show that overexpression of MRP1/ABCC1 facilitates the elimination of therapeutic agents from cancer cells and confers drug resistance in those patients. Research studies also show that elevated expression of MRP1/ABCC1 is a negative prognostic marker for breast cancer and small cell lung cancer, as the level of MRP1/ABCC1 is predictive of the response and toxicity of chemotherapeutic agents in those patients (6-10).


1.  Cole, S.P. et al. (1992) Science 258, 1650-4.

2.  Pajic, M. et al. (2005) Cancer Lett 228, 241-6.

3.  Deeley, R.G. and Cole, S.P. (2006) FEBS Lett 580, 1103-11.

4.  Atalay, C. et al. (2006) Tumour Biol 27, 309-18.

5.  Sánchez, C. et al. (2011) Prostate 71, 1810-7.

6.  Nooter, K. et al. (1997) Br J Cancer 76, 486-93.

7.  Hsia, T.C. et al. (2002) Lung 180, 173-9.

8.  Kuo, T.H. et al. (2003) Nucl Med Biol 30, 627-32.

9.  Sánchez, C. et al. (2009) Prostate 69, 1448-59.

10.  Vulsteke, C. et al. (2013) Ann Oncol 24, 1513-25.


Entrez-Gene Id 4363
Swiss-Prot Acc. P33527


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
Tween is a registered trademark of ICI Americas, Inc.